Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current Assets:
Cash and cash equivalents	$ 13,203,625	$ 13,452,775
Marketable securities	37,424,221	86,165,532
Accounts receivable, net of allowance for doubtful accounts of $74,546 and $54,177 at June 30, 2016 and 2015, respectively	513,992	345,627
Inventory	350,524	584,424
Other receivables	236,768	857,068
Prepaid expenses	1,038,155	1,136,103
Other current assets	183,820	945,673
Total current assets	52,951,105	103,487,202
Property and equipment, net	3,969,163	2,241,838
Value of life insurance policies		20,566
Other long-term assets	30,000	30,000
Total Assets	56,950,268	105,779,606
Current Liabilities:
Accounts payable and accrued expenses	15,188,189	11,808,223
Deferred revenues	235,372	271,667
Total current liabilities	15,423,561	12,079,890
Convertible senior notes – net of unamortized debt issuance costs of $2,645,602 and $3,375,423 at June 30, 2016 and 2015, respectively	97,354,398	96,624,577
Other liabilities	1,699,276	1,599,760
Commitments and Contingencies (Note 13)
Stockholders' Deficit:
Preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2016 and at June 30, 2015
Common stock, $.01 par value; authorized 155,000,000 shares; issued 95,867,298 shares and outstanding 95,832,573 shares at June 30, 2016; issued 94,546,578 shares and outstanding 94,511,853 shares at June 30, 2015	958,672	945,465
Capital contributed in excess of par	311,320,651	305,229,354
Treasury stock, at cost, 34,725 shares at June 30, 2016 and at June 30, 2015	(458,370)	(458,370)
Accumulated deficit	(368,504,954)	(309,468,004)
Accumulated other comprehensive loss	(132,226)	(161,092)
Total Immunomedics, Inc. stockholders' deficit	(56,816,227)	(3,912,647)
Noncontrolling interest in subsidiary	(710,740)	(611,974)
Total stockholders’ deficit	(57,526,967)	(4,524,621)
Total Liabilities and Stockholders' Deficit	$ 56,950,268	$ 105,779,606